Activation of the pre-BCR induces downstream signaling via phosphorylation of tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAMs) of the cytoplasmic tails of CD79a/CD79b.3 Due to its high abundance on mature B cells, the BCR complex has become an important target for diffuse large B-cell lymphoma (DLBCL) treatment and the CD79b antibody drug conjugate (ADC) Polatuzumab Vedotin (PolVed) has shown therapeutic efficacy in DLBCL-frontline treatment.4 This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.